Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models

Cancer Gene Therapy

Volumn 18, Issue 12, 2011, Pages 871-883

  Predina, J D ^a   Judy, B ^a   Aliperti, L A ^a   Fridlender, Z G ^b   Blouin, A ^a   Kapoor, V ^b   Laguna, B ^a   Nakagawa, H ^b   Rustgi, A K ^b   Aguilar, L ^c   Aguilar Cordova, E ^c   Albelda, S M ^b   Singhal, S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Advantagene   (United States)

Author keywords

animal models; esophageal carcinoma; immunotherapy; neoadjuvant therapy; surgery

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYCLIN D1; FLUOROURACIL; GANCICLOVIR; PROTEIN P53; THYMIDINE KINASE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGUS CARCINOMA; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; CYTOTOXICITY, IMMUNOLOGIC; ESOPHAGEAL NEOPLASMS; FEMALE; GENE THERAPY; GENES, RAS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; THYMIDINE KINASE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS; SIMPLEXVIRUS;

EID: 81155150019     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.56     Document Type: Article

References (43)

1. NCI Surveillance, Epidemiology, and End Results (SEER) Program. Nov 2009 Sub (1973-2007) oKatrian/Rita Population Adjustment4 edn. SEER Stat Database: Bethesda, MD, 2009.
2. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337. (Pubitemid 46207006)
3. Juergens RA, Forastiere A. Combined modality therapy of esophageal cancer. J Natl Compr Canc Netw 2008; 6: 851-860; quiz 861.
4. Zhang X, Watson DI, Jamieson GG, Bessell JR, Devitt PG. Neoadjuvant chemoradiotherapy for esophageal carcinoma. Dis Esophagus 2005; 18: 104-108. (Pubitemid 40975422)
5. Neves S, Faneca H, Bertin S, Konopka K, Duzgunes N, Pierrefite-Carle V et al. Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. Cancer Gene Ther 2009; 16: 91-101.
6. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Therapy 1997; 4: 1322-1329. (Pubitemid 28004591)
7. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999; 163: 1398-1408. (Pubitemid 29352760)
8. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour:HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274. (Pubitemid 27253001)
9. Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda SM, Kaiser LR. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg 1995; 109: 626-630; discussion 630-631.
10. Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996; 7: 141-148. (Pubitemid 26044833)
11. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133. (Pubitemid 28463929)
12. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-1092. (Pubitemid 28236516)
13. Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S et al. Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003; 10: 353-364. (Pubitemid 36528779)
14. Okada T, Shah M, Higginbotham JN, Li Q, Wildner O, Walbridge S et al. AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Therapy 2001; 8: 1315-1322. (Pubitemid 32834300)
15. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225. (Pubitemid 28371055)
16. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E et al. Biological response determinants in HSVtk+ ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13: 716-728.
17. Hasenburg A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001; 83: 549-554. (Pubitemid 33139718)
18. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955-1967. (Pubitemid 33116762)
19. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1: 195-203.
20. van der Linden RR, Haagmans BL, Mongiat-Artus P, van Doornum GJ, Kraaij R, Kadmon D et al. Virus specific immune responses after human neoadjuvant adenovirusmediated suicide gene therapy for prostate cancer. Eur Urol 2005; 48: 153-161. (Pubitemid 40835614)
21. Lambright ES, Amin K, Wiewrodt R, Force SD, Lanuti M, Propert KJ et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Therapy 2001; 8: 946-953. (Pubitemid 32600151)
22. Lambright ES, Kang EH, Force S, Lanuti M, Caparrelli D, Kaiser LR et al. Effect of preexisting antiherpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2000; 2: 387-393.
23. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453. (Pubitemid 41507705)
24. Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2006; 65: 84-90.
25. Rainov NG, Fels C, Droege JW, Schafer C, Kramm CM, Chou TC. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther 2001; 8: 662-668. (Pubitemid 32912240)
26. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
27. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36. (Pubitemid 32195242)
28. Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R et al. A mouse model of human oral-esophageal cancer. J Clin Invest 2002; 110: 761-769.
29. Nakagawa H, Wang TC, Zukerberg L, Odze R, Togawa K, May GH et al. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 1997; 14: 1185-1190. (Pubitemid 27141920)
30. Takaoka M, Harada H, Deramaudt TB, Oyama K, Andl CD, Johnstone CN et al. Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction. Oncogene 2004; 23: 6760-6768. (Pubitemid 39280007)
31. Nishihira T, Kasai M, Mori S, Watanabe T, Kuriya Y, Suda M et al. Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gann 1979; 70: 575-584. (Pubitemid 10139660)
32. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767-5772.
33. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65: 7580-7584. (Pubitemid 41297228)
34. Marsman WA, Wesseling JG, El Bouch A, Bosma PJ, van Lanschot JJ. Adenoviral serotypes in gene therapy for esophageal carcinoma. J Surg Res 2007; 140: 50-54. (Pubitemid 46669552)
35. Buskens CJ, Marsman WA, Wesseling JG, Offerhaus GJ, Yamamoto M, Curiel DT et al. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg 2003; 238: 815-824; discussion 825-826.
36. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001; 3: 536-542. (Pubitemid 32509847)
37. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839-844. (Pubitemid 30437283)
38. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010; 18: 1947-1959.
39. Curtis JL, Punturieri A. Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity. Am J Respir Cell Mol Biol 2003; 28: 541-545. (Pubitemid 36543399)
40. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 2002; 51: 583-595. (Pubitemid 35440511)
41. Bursuker I, North RJ. Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer 1986; 37: 275-281. (Pubitemid 16152452)
42. Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T et al. Suppression of cellular immunity by surgical stress. Surgery 2000; 127: 329-336. (Pubitemid 30140632)
43. Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M et al. Acute wounds accelerate tumorigenesis by a T celldependent mechanism. Cancer Res 2008; 68: 7278-7282.